INB-03
- Generic Name
- INB-03
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
- Conditions
- Central Nervous System DiseasesTauopathiesMental DisordersAlzheimer DiseaseBrain DiseasesDementiaNeurodegenerative DiseasesNeurocognitive DisordersNervous System Diseases
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05522387
- Locations
- 🇦🇺
Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia
🇦🇺KaRa MINDS, Macquarie Park, New South Wales, Australia
🇦🇺Neuro Trials Victoria Pty Ltd T/A NeuroCentrix, Carlton, Victoria, Australia
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
- Conditions
- DementiaMild Cognitive Impairment (MCI)Alzheimer DiseaseBrain DiseasesNervous System DiseasesCentral Nervous System DiseasesTauopathiesNeurodegenerative DiseasesMental Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Inmune Bio, Inc.
- Registration Number
- NCT05321498
A Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation
- Conditions
- Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersMild Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT05318976
- Locations
- 🇬🇧
INmune Bio Investigational Site, Winchester, United Kingdom
INB03 for the Treatment of Pulmonary Complications From COVID-19
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT04370236
- Locations
- 🇺🇸
NEA Baptist, Jonesboro, Arkansas, United States
🇺🇸Mississippi Baptist, Kosciusko, Mississippi, United States
🇺🇸Jewish Hospital, Louisville, Kentucky, United States
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03943264
- Locations
- 🇦🇺
KaRa MINDS, Macquarie Park, New South Wales, Australia
🇦🇺Central Adelaide Local Health Network, Woodville, South Australia, Australia
🇦🇺Mater Medical Research Institute, Brisbane, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.